<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03514641</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-603</org_study_id>
    <nct_id>NCT03514641</nct_id>
  </id_info>
  <brief_title>An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension</brief_title>
  <official_title>An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin Tablets, 20 mg, for the Management of Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This integrated assessment consists of two studies, 603A and 603B, to be carried out&#xD;
      sequentially in a common study population. Participating subjects informed of the trial&#xD;
      design and their consent to participate in both studies were to be obtained in a single&#xD;
      consent form. Approximately 680 male or female adult subjects were to be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      THR-1442-C-603 is an integrated assessment of the potential utility of bexagliflozin tablets,&#xD;
      20 mg for the treatment of essential hypertension. It is composed of two studies, 603A and&#xD;
      603B, measuring effects in a common population.&#xD;
&#xD;
      603A was a multicenter double-blind parallel group placebo-controlled study conducted to&#xD;
      determine the placebo-adjusted change from baseline to week 12 in the mean ambulatory&#xD;
      systolic blood pressure (SBP) of approximately 680 subjects considered generally&#xD;
      representative of the adult hypertensive population in the United States. Secondary endpoints&#xD;
      included the placebo-adjusted change from baseline to week 12 of the mean office seated&#xD;
      systolic blood pressure, the change to week 12 of the mean ambulatory and mean office seated&#xD;
      diastolic blood pressure, the proportion of subjects achieving prespecified goals for&#xD;
      absolute systolic and diastolic blood pressure as well as prespecified goals for reduction in&#xD;
      systolic and diastolic blood pressure, measured by ambulatory and seated office measurement&#xD;
      methodology.&#xD;
&#xD;
      A603B was a multicenter double-blind parallel group placebo-controlled randomized withdrawal&#xD;
      study conducted to determine the durability of the antihypertensive effect of bexagliflozin&#xD;
      tablets, 20 mg, in a population not pre-selected for existing diabetes. All subjects entered&#xD;
      a 12 week run-in period during which they self-administered open label bexagliflozin tablets,&#xD;
      20 mg once daily. At week 12 a baseline ambulatory blood pressure monitoring (ABPM)&#xD;
      measurement was made, and the subjects were randomized one to one to receive either&#xD;
      bexagliflozin tablets, 20 mg or bexagliflozin tablets, placebo. After a 12 week treatment&#xD;
      period a second ABPM measurement was made. The primary endpoint was the intergroup difference&#xD;
      in the change from baseline in the mean SBP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The primary endpoint of study 603A is the change from baseline (Day 1) to week 12 in the 24-hour average SBP of the bexagliflozin group compared to the placebo group using a superiority testing at an overall two-sided 0.05 level of significance.&#xD;
The primary endpoint of study 603B is the change from week 12 (cumulative week 24) to week 24 (cumulative week 36) in the 24-hour average SBP in the bexagliflozin group compared to the placebo group using a superiority testing at an overall two-sided 0.05 level of significance.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study 603A: bexagliflozin tablets, 20 mg or placebo&#xD;
Study 603B week 1 to week 12: bexagliflozin tablets, 20 mg, open-labeled&#xD;
Study 603B week 13 to week 24: bexagliflozin tablets, 20 mg or placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36</measure>
    <time_frame>Change from week 24 to week 36</time_frame>
    <description>Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>603A, Reduction of Mean Ambulatory Systolic Blood Pressure</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Proportion of subjects who achieve a reduction of mean ambulatory systolic blood pressure of 10 mm Hg or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603A, Mean Ambulatory Systolic Blood Pressure of 135 mm Hg or Less</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Proportion of subjects who achieve a mean ambulatory systolic blood pressure of 135 mm Hg or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603A, Change in Seated Office Systolic Blood Pressure</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Placebo-adjusted change in seated office systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603A, Seated Office Systolic Blood Pressure of 140 mm Hg or Less</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Proportion of subjects who achieve a seated office systolic blood pressure of 140 mm Hg or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603A, Change in Mean Ambulatory Diastolic Blood Pressure</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Placebo-adjusted change in mean ambulatory diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603A, Mean Ambulatory Diastolic Blood Pressure of 87 mm Hg or Less</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Proportion of subjects who achieve a mean ambulatory diastolic blood pressure of 87 mm Hg or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603A, Reduction of Mean Ambulatory Diastolic Blood Pressure of 4 mm Hg or Greater</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Proportion of subjects who achieve a reduction of mean ambulatory diastolic blood pressure of 4 mm Hg or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603A, Change in Seated Office Diastolic Blood Pressure</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Placebo-adjusted change in seated office diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603A, Seated Office Diastolic Blood Pressure of 90 mm Hg or Less</measure>
    <time_frame>Baseline (Day 1) to week 12</time_frame>
    <description>Proportion of subjects who achieve a mean seated office diastolic blood pressure of 90 mm Hg or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603B, Change in Seated Office Systolic Blood Pressure</measure>
    <time_frame>Week 12 (cumulative week 24) to Week 24 (cumulative week 36)</time_frame>
    <description>Placebo-adjusted change from week 12 to week 24 in seated office systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603B, Change in Mean Ambulatory Diastolic Blood Pressure</measure>
    <time_frame>Week 12 (cumulative week 24) to Week 24 (cumulative week 36)</time_frame>
    <description>Placebo-adjusted change in mean ambulatory diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>603B, Change in Seated Office Diastolic Blood Pressure</measure>
    <time_frame>Week 12 (cumulative week 24) to Week 24 (cumulative week 36)</time_frame>
    <description>Placebo-adjusted change from week 12 to week 24 in seated office diastolic blood pressure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Integrated 603A and 603B, Effects on Mean Ambulatory Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Baseline (Day 1) to cumulative week 36</time_frame>
    <description>Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on mean ambulatory systolic and diastolic blood pressure after 12 weeks of bexagliflozin treatment, as well as longer treatment periods, i.e., 24 weeks or 36 weeks of bexagliflozin treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Integrated 603A and 603B, Effects on Seated Office Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Baseline (Day 1) to cumulative week 36</time_frame>
    <description>Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on seated office systolic and diastolic blood pressure over time</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">673</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Bexagliflozin tablet, 20 mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <other_name>EGT0001442</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (inactive) tablet to match the active drug</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To be eligible for randomization a prospective subject was to be:&#xD;
&#xD;
          -  Male or female of age ≥ 20 years&#xD;
&#xD;
          -  Diagnosed with essential hypertension and exhibiting an office seated SBP ≥ 140 and &lt;&#xD;
             180 mm Hg&#xD;
&#xD;
          -  Unmedicated or prescribed no more than 4 agents for hypertension. Unmedicated subjects&#xD;
             were subjects who had never taken medications for hypertension or had not taken any&#xD;
             anti-hypertensive medication for at least 3 months. A stable dose meant no change in&#xD;
             dose or frequency had taken place in the 4 weeks prior to the screening visit&#xD;
&#xD;
          -  If female and of childbearing potential, willing to use an adequate method of&#xD;
             contraception and to not become pregnant for the duration of the study.&#xD;
&#xD;
          -  Willing and able to return for all clinic visits and to complete all study-required&#xD;
             procedures&#xD;
&#xD;
          -  Able to self-medicate during the run-in period, omitting no more than one day of&#xD;
             dosing&#xD;
&#xD;
          -  Shown to have a seated SBP ≥ 140 and &lt; 180 mm Hg&#xD;
&#xD;
          -  Shown to exhibit a mean 24 h SBP ≥ 135 mm Hg&#xD;
&#xD;
        Prospective participants exhibiting any of the following characteristics were to be&#xD;
        excluded from the study:&#xD;
&#xD;
          -  Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young (MODY)&#xD;
&#xD;
          -  Known history of secondary or malignant hypertension&#xD;
&#xD;
          -  Seated diastolic blood pressure (DBP) &gt;110 mm Hg at screening&#xD;
&#xD;
          -  Taking insulin for diabetes&#xD;
&#xD;
          -  Prescribed more than 4 anti-hypertension medications&#xD;
&#xD;
          -  Having a genitourinary tract infection within 6 weeks of screening or history of ≥ 3&#xD;
             genitourinary infections requiring treatment within the last 6 months&#xD;
&#xD;
          -  Having cancer, active or in remission for &lt; 3 years&#xD;
&#xD;
          -  History of alcohol or illicit drug abuse in the past 2 years&#xD;
&#xD;
          -  History of myocardial infarction, stroke or hospitalization for heart failure in the&#xD;
             prior 6 months&#xD;
&#xD;
          -  Previous exposure to bexagliflozin or EGT0001474&#xD;
&#xD;
          -  History of hypertensive emergency&#xD;
&#xD;
          -  History of sodium glucose linked transporter 2 (SGLT2) inhibitor treatment in the last&#xD;
             3 months&#xD;
&#xD;
          -  Known intolerance or allergy to SGTL2 inhibitors&#xD;
&#xD;
          -  Any condition, disease, disorder, or clinically relevant laboratory abnormality that,&#xD;
             in the opinion of the PI, would jeopardize the subject's appropriate participation in&#xD;
             this study or obscure the effects of treatment&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Current participation in another interventional trial or having been exposed to an&#xD;
             investigational drug within 30 days or 7 half-lives of screening, whichever is longer&#xD;
&#xD;
          -  Arm circumference too large or small to allow accurate ambulatory monitoring&#xD;
&#xD;
          -  History of kidney transplant&#xD;
&#xD;
          -  Occupational or other lifestyle factors that could hamper the collection of valid ABPM&#xD;
             data&#xD;
&#xD;
          -  Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase &gt;&#xD;
             1.5 × upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome);&#xD;
             or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 × ULN&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR), as calculated by the modification of diet&#xD;
             in renal disease study equation (MDRD), &lt; 45 mL/min/1.73 m2 or requiring dialysis&#xD;
&#xD;
          -  HbA1c &gt; 9.5%&#xD;
&#xD;
          -  Positive urine pregnancy test for female subjects of child bearing potential&#xD;
&#xD;
          -  Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase &gt;&#xD;
             1.5 × upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome);&#xD;
             or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 × ULN&#xD;
&#xD;
          -  eGFR, as calculated by the modification of diet in renal disease study equation&#xD;
             (MDRD), &lt; 45 mL/min/1.73 m2 or requiring dialysis&#xD;
&#xD;
          -  HbA1c &gt; 9.5%&#xD;
&#xD;
          -  Positive urine pregnancy test for female subjects of child bearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Allegretti, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <zip>36535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Gulf Shores</city>
        <state>Alabama</state>
        <zip>36542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <zip>95628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>San Gabriel</city>
        <state>California</state>
        <zip>91776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Lithonia</city>
        <state>Georgia</state>
        <zip>30058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Versailles</city>
        <state>Kentucky</state>
        <zip>40383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <zip>10530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Grove City</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Hatboro</city>
        <state>Pennsylvania</state>
        <zip>19040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 2</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2018</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>August 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2021</results_first_posted>
  <disposition_first_submitted>January 31, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 25, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 21, 2021</disposition_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03514641/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03514641/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In the first part of the study (603A), the subjects were randomized to receive bexagliflozin or placebo for 12 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>603A: Bexagliflozin Tablets, 20 mg</title>
          <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>603A: Placebo Tablets</title>
          <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>603B: Bexagliflozin Tablets, 20 mg</title>
          <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks from week 24 to week 36 (cumulative)</description>
        </group>
        <group group_id="P4">
          <title>603B: Placebo Tablets</title>
          <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks from week 24 to week 36 (cumulative)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>603A: 0-12 Week Study Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="334"/>
                <participants group_id="P2" count="339"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="319"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>24 hr ABPM not enough readings</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>603B: 24-36 Week Study Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">The second part of study only applies to subjects in 603B</participants>
                <participants group_id="P2" count="0">The second part of study only applies to subjects in 603B</participants>
                <participants group_id="P3" count="281">The subjects were re-randomized in 603B</participants>
                <participants group_id="P4" count="281">The subjects were re-randomized in 603B</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="267"/>
                <participants group_id="P4" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>24 hr ABPM not enough readings</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>To avoid being double-counting of the participants, the number of baseline participants has been entered as &quot;0&quot; for 603B.&#xD;
Subjects in 603B study had completed 603A study and were qualified to be re-randomized in 603B study.</population>
      <group_list>
        <group group_id="B1">
          <title>603A: Bexagliflozin Tablets, 20 mg</title>
          <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>603 A: Placebo Tablets</title>
          <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>603B: Bexagliflozin Tablets, 20 mg</title>
          <description>Each eligible subject who have completed 603A including two successful 24-h ABPM sessions at 603A baseline and at week 12, and have completed the 12 weeks open labeled bexagliflozin run-in period with a successful 24-h ABPM session at week 12 of 603B, will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>603B: Placebo Tablets</title>
          <description>Each eligible subject who have completed 603A including two successful 24-h ABPM sessions at 603A baseline and at week 12, and have completed the 12 weeks open labeled bexagliflozin run-in period with a successful 24-h ABPM session at week 12 of 603B, will receive placebo (inactive tablets) once daily for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="334"/>
            <count group_id="B2" value="339"/>
            <count group_id="B3" value="281"/>
            <count group_id="B4" value="281"/>
            <count group_id="B5" value="1235"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="11.32"/>
                    <measurement group_id="B2" value="58.3" spread="12.06"/>
                    <measurement group_id="B5" value="58.9" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="59.9" spread="11.39"/>
                    <measurement group_id="B4" value="59.2" spread="11.78"/>
                    <measurement group_id="B5" value="59.6" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="266"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="167"/>
                    <measurement group_id="B5" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="619"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="262"/>
                    <measurement group_id="B5" value="516"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="439"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="195"/>
                    <measurement group_id="B5" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.29" spread="6.522"/>
                    <measurement group_id="B2" value="32.90" spread="6.527"/>
                    <measurement group_id="B5" value="32.59" spread="6.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="32.22" spread="6.952"/>
                    <measurement group_id="B4" value="33.17" spread="6.144"/>
                    <measurement group_id="B5" value="32.69" spread="6.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight at Baseline</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.36" spread="22.643"/>
                    <measurement group_id="B2" value="97.47" spread="22.673"/>
                    <measurement group_id="B5" value="96.42" spread="22.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="95.71" spread="24.321"/>
                    <measurement group_id="B4" value="97.55" spread="21.003"/>
                    <measurement group_id="B5" value="96.63" spread="22.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Diabetes</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B5" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B5" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="215"/>
                    <measurement group_id="B5" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of any antihypertension medication</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B5" value="545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="233"/>
                    <measurement group_id="B4" value="226"/>
                    <measurement group_id="B5" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR) Mean</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.64" spread="17.438"/>
                    <measurement group_id="B2" value="84.42" spread="19.710"/>
                    <measurement group_id="B5" value="83.53" spread="18.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="78.75" spread="18.971"/>
                    <measurement group_id="B4" value="77.95" spread="18.871"/>
                    <measurement group_id="B5" value="78.35" spread="18.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ambulatory Blood Pressure Monitoring (ABPM) at baseline</title>
          <population>Subjects who experienced worsening of their hypertension prior to the 6-week visit were not to undergo ABPM measurement.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period; SBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="329"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="668"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147.58" spread="9.640"/>
                    <measurement group_id="B2" value="147.48" spread="10.064"/>
                    <measurement group_id="B5" value="147.53" spread="9.850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603A: 0-12 Week Study Period; DBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="329"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="668"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.04" spread="9.240"/>
                    <measurement group_id="B2" value="84.97" spread="10.216"/>
                    <measurement group_id="B5" value="85.01" spread="9.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period; SBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="136.30" spread="13.844"/>
                    <measurement group_id="B4" value="135.62" spread="13.510"/>
                    <measurement group_id="B5" value="135.96" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period; DBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="79.58" spread="10.471"/>
                    <measurement group_id="B4" value="79.20" spread="10.571"/>
                    <measurement group_id="B5" value="79.39" spread="10.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Office seated SBP and DBP at baseline</title>
          <population>First row corresponds to participants only in 603A. Second row corresponds to participants only in 603B.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>603A: 0-12 Week Study Period; SBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.44" spread="10.513"/>
                    <measurement group_id="B2" value="155.84" spread="10.335"/>
                    <measurement group_id="B5" value="156.14" spread="10.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603A: 0-12 Week Study Period; DBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="334"/>
                    <count group_id="B2" value="339"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.29" spread="10.269"/>
                    <measurement group_id="B2" value="91.48" spread="10.619"/>
                    <measurement group_id="B5" value="91.39" spread="10.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period; SBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="141.18" spread="16.231"/>
                    <measurement group_id="B4" value="140.69" spread="14.960"/>
                    <measurement group_id="B5" value="140.94" spread="15.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>603B: 12-36 Week Study Period; DBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="281"/>
                    <count group_id="B5" value="562"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="84.75" spread="11.623"/>
                    <measurement group_id="B4" value="85.28" spread="11.588"/>
                    <measurement group_id="B5" value="84.55" spread="10.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12</title>
        <description>Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared to placebo</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12</title>
          <description>Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared to placebo</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.86" spread="0.642"/>
                    <measurement group_id="O2" value="-6.15" spread="0.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>LS Means difference</param_type>
            <param_value>-2.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.47</ci_lower_limit>
            <ci_upper_limit>-0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36</title>
        <description>Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared placebo</description>
        <time_frame>Change from week 24 to week 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36</title>
          <description>Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared placebo</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.680"/>
                    <measurement group_id="O2" value="2.74" spread="0.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0117</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.32</ci_lower_limit>
            <ci_upper_limit>-0.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603A, Reduction of Mean Ambulatory Systolic Blood Pressure</title>
        <description>Proportion of subjects who achieve a reduction of mean ambulatory systolic blood pressure of 10 mm Hg or greater</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603A, Reduction of Mean Ambulatory Systolic Blood Pressure</title>
          <description>Proportion of subjects who achieve a reduction of mean ambulatory systolic blood pressure of 10 mm Hg or greater</description>
          <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.35" upper_limit="0.46"/>
                    <measurement group_id="O2" value="0.34" lower_limit="0.29" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1317</p_value>
            <p_value_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</p_value_desc>
            <method>Covariance</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603A, Mean Ambulatory Systolic Blood Pressure of 135 mm Hg or Less</title>
        <description>Proportion of subjects who achieve a mean ambulatory systolic blood pressure of 135 mm Hg or less</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603A, Mean Ambulatory Systolic Blood Pressure of 135 mm Hg or Less</title>
          <description>Proportion of subjects who achieve a mean ambulatory systolic blood pressure of 135 mm Hg or less</description>
          <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
          <units>Proportion of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.34" upper_limit="0.46"/>
                    <measurement group_id="O2" value="0.29" lower_limit="0.24" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0113</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603A, Change in Seated Office Systolic Blood Pressure</title>
        <description>Placebo-adjusted change in seated office systolic blood pressure</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603A, Change in Seated Office Systolic Blood Pressure</title>
          <description>Placebo-adjusted change in seated office systolic blood pressure</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.24" spread="0.799"/>
                    <measurement group_id="O2" value="-6.61" spread="0.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.83</ci_lower_limit>
            <ci_upper_limit>-2.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603A, Seated Office Systolic Blood Pressure of 140 mm Hg or Less</title>
        <description>Proportion of subjects who achieve a seated office systolic blood pressure of 140 mm Hg or less</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline seated office SBP/DBP value as a fixed effect covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603A, Seated Office Systolic Blood Pressure of 140 mm Hg or Less</title>
          <description>Proportion of subjects who achieve a seated office systolic blood pressure of 140 mm Hg or less</description>
          <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline seated office SBP/DBP value as a fixed effect covariate.</population>
          <units>Proportion of subjects</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0.33" upper_limit="0.44"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.21" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603A, Change in Mean Ambulatory Diastolic Blood Pressure</title>
        <description>Placebo-adjusted change in mean ambulatory diastolic blood pressure</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603A, Change in Mean Ambulatory Diastolic Blood Pressure</title>
          <description>Placebo-adjusted change in mean ambulatory diastolic blood pressure</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.92" spread="0.349"/>
                    <measurement group_id="O2" value="-3.08" spread="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0863</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.79</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603A, Mean Ambulatory Diastolic Blood Pressure of 87 mm Hg or Less</title>
        <description>Proportion of subjects who achieve a mean ambulatory diastolic blood pressure of 87 mm Hg or less</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603A, Mean Ambulatory Diastolic Blood Pressure of 87 mm Hg or Less</title>
          <description>Proportion of subjects who achieve a mean ambulatory diastolic blood pressure of 87 mm Hg or less</description>
          <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
          <units>Proportion of subjects</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" lower_limit="0.41" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.37" lower_limit="0.32" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0232</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603A, Reduction of Mean Ambulatory Diastolic Blood Pressure of 4 mm Hg or Greater</title>
        <description>Proportion of subjects who achieve a reduction of mean ambulatory diastolic blood pressure of 4 mm Hg or greater</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603A, Reduction of Mean Ambulatory Diastolic Blood Pressure of 4 mm Hg or Greater</title>
          <description>Proportion of subjects who achieve a reduction of mean ambulatory diastolic blood pressure of 4 mm Hg or greater</description>
          <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
          <units>Proportion of subjects</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.83" upper_limit="0.92"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.73" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0140</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>2.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603A, Change in Seated Office Diastolic Blood Pressure</title>
        <description>Placebo-adjusted change in seated office diastolic blood pressure</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603A, Change in Seated Office Diastolic Blood Pressure</title>
          <description>Placebo-adjusted change in seated office diastolic blood pressure</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.44" spread="0.504"/>
                    <measurement group_id="O2" value="-2.13" spread="0.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.70</ci_lower_limit>
            <ci_upper_limit>-0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603A, Seated Office Diastolic Blood Pressure of 90 mm Hg or Less</title>
        <description>Proportion of subjects who achieve a mean seated office diastolic blood pressure of 90 mm Hg or less</description>
        <time_frame>Baseline (Day 1) to week 12</time_frame>
        <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603A, Seated Office Diastolic Blood Pressure of 90 mm Hg or Less</title>
          <description>Proportion of subjects who achieve a mean seated office diastolic blood pressure of 90 mm Hg or less</description>
          <population>The full model is a logistic regression that includes diabetes status (history of type 2 diabetes mellitus or not), eGFR at screening, pre-treatment status (presently medicated for hypertension or not), treatment, and the baseline 24-hour mean SBP/DBP value as a fixed effect covariate.</population>
          <units>Proportion of subjects</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.59" upper_limit="0.71"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.47" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0094</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603B, Change in Seated Office Systolic Blood Pressure</title>
        <description>Placebo-adjusted change from week 12 to week 24 in seated office systolic blood pressure</description>
        <time_frame>Week 12 (cumulative week 24) to Week 24 (cumulative week 36)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603B, Change in Seated Office Systolic Blood Pressure</title>
          <description>Placebo-adjusted change from week 12 to week 24 in seated office systolic blood pressure</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.846"/>
                    <measurement group_id="O2" value="5.18" spread="0.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0083</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.57</ci_lower_limit>
            <ci_upper_limit>-0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603B, Change in Mean Ambulatory Diastolic Blood Pressure</title>
        <description>Placebo-adjusted change in mean ambulatory diastolic blood pressure</description>
        <time_frame>Week 12 (cumulative week 24) to Week 24 (cumulative week 36)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603B, Change in Mean Ambulatory Diastolic Blood Pressure</title>
          <description>Placebo-adjusted change in mean ambulatory diastolic blood pressure</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.369"/>
                    <measurement group_id="O2" value="0.94" spread="0.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1085</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.87</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>603B, Change in Seated Office Diastolic Blood Pressure</title>
        <description>Placebo-adjusted change from week 12 to week 24 in seated office diastolic blood pressure</description>
        <time_frame>Week 12 (cumulative week 24) to Week 24 (cumulative week 36)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin Tablets, 20 mg</title>
            <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
            <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>603B, Change in Seated Office Diastolic Blood Pressure</title>
          <description>Placebo-adjusted change from week 12 to week 24 in seated office diastolic blood pressure</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.507"/>
                    <measurement group_id="O2" value="1.76" spread="0.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0837</p_value>
            <method>Covariance</method>
            <method_desc>Covariance model diabetes status, eGFR at screening, pre-treatment status, treatment, and baseline 24-hour mean SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.67</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Integrated 603A and 603B, Effects on Mean Ambulatory Systolic and Diastolic Blood Pressure</title>
        <description>Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on mean ambulatory systolic and diastolic blood pressure after 12 weeks of bexagliflozin treatment, as well as longer treatment periods, i.e., 24 weeks or 36 weeks of bexagliflozin treatment.</description>
        <time_frame>Baseline (Day 1) to cumulative week 36</time_frame>
        <population>Number of subjects with baseline and value after specified weeks of exposure to Bexagliflozin</population>
        <group_list>
          <group group_id="O1">
            <title>Effect on Mean Ambulatory SBP</title>
            <description>Effect on ABPM SBP after 12, 24, and 36 weeks of cumulative exposure to Bexagliflozin</description>
          </group>
          <group group_id="O2">
            <title>Effect on Mean Ambulatory DBP</title>
            <description>Effect on ABPM DBP after 12, 24, and 36 weeks of cumulative exposure to Bexagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Integrated 603A and 603B, Effects on Mean Ambulatory Systolic and Diastolic Blood Pressure</title>
          <description>Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on mean ambulatory systolic and diastolic blood pressure after 12 weeks of bexagliflozin treatment, as well as longer treatment periods, i.e., 24 weeks or 36 weeks of bexagliflozin treatment.</description>
          <population>Number of subjects with baseline and value after specified weeks of exposure to Bexagliflozin</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="649"/>
                <count group_id="O2" value="649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="649"/>
                    <count group_id="O2" value="555"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.595" lower_limit="-8.565" upper_limit="-6.625"/>
                    <measurement group_id="O2" value="-3.269" lower_limit="-3.773" upper_limit="-2.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="395"/>
                    <count group_id="O2" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.262" lower_limit="-10.559" upper_limit="-7.965"/>
                    <measurement group_id="O2" value="-4.044" lower_limit="-4.720" upper_limit="-3.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.454" lower_limit="-14.988" upper_limit="-9.921"/>
                    <measurement group_id="O2" value="-5.566" lower_limit="-6.825" upper_limit="-4.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Integrated 603A and 603B, Effects on Seated Office Systolic and Diastolic Blood Pressure</title>
        <description>Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on seated office systolic and diastolic blood pressure over time</description>
        <time_frame>Baseline (Day 1) to cumulative week 36</time_frame>
        <population>Number of subjects with baseline and value after specified weeks of exposure to Bexagliflozin</population>
        <group_list>
          <group group_id="O1">
            <title>Effect on Seated Office SBP</title>
            <description>Effect on seated office SBP after 6, 12, 18, 24, and 36 weeks of cumulative exposure to Bexagliflozin</description>
          </group>
          <group group_id="O2">
            <title>Effect on Seated Office DBP</title>
            <description>Effect on seated office DBP after 6, 12, 18, 24, and 36 weeks of cumulative exposure to Bexagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Integrated 603A and 603B, Effects on Seated Office Systolic and Diastolic Blood Pressure</title>
          <description>Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on seated office systolic and diastolic blood pressure over time</description>
          <population>Number of subjects with baseline and value after specified weeks of exposure to Bexagliflozin</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="649"/>
                <count group_id="O2" value="649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="602"/>
                    <count group_id="O2" value="602"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.43" spread="16.399"/>
                    <measurement group_id="O2" value="-4.50" spread="9.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="582"/>
                    <count group_id="O2" value="582"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.91" spread="15.777"/>
                    <measurement group_id="O2" value="-4.10" spread="9.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.46" spread="16.000"/>
                    <measurement group_id="O2" value="-5.87" spread="9.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.53" spread="18.830"/>
                    <measurement group_id="O2" value="-4.92" spread="10.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.71" spread="16.975"/>
                    <measurement group_id="O2" value="-6.47" spread="9.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For 603A, adverse events were collected from baseline to Week 12. For 603B, adverse events were collected from Week 24 to Week 36.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>603A: Bexagliflozin Tablets, 20 mg</title>
          <description>Each subject will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>603A: Placebo Tablets</title>
          <description>Each subject will receive placebo (inactive tablet) once daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>603B: Bexagliflozin Tablets, 20 mg</title>
          <description>Each eligible subject who have completed 603A including two successful 24-h ABPM sessions at 603A baseline and at week 12, and have completed the 12 weeks open labeled bexagliflozin run-in period with a successful 24-h ABPM session at week 12 of 603B, will receive bexagliflozin tablets, 20 mg once daily for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>603B: Placebo Tablets</title>
          <description>Each eligible subject who have completed 603A including two successful 24-h ABPM sessions at 603A baseline and at week 12, and have completed the 12 weeks open labeled bexagliflozin run-in period with a successful 24-h ABPM session at week 12 of 603B, will receive placebo tablets (inactive), 20 mg once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level below therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of salivary gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="339"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="334"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="339"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="281"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="339"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="281"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="339"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="339"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="339"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator has no right to publish the study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Albert Collinson</name_or_title>
      <organization>Theracos Sub, LLC</organization>
      <phone>(508) 688-4221</phone>
      <email>acollinson@theracos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

